Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia
Condition(s):Congenital Myasthenic SyndromeLast Updated:June 2, 2023No longer available
Hide Studies Not Open or Pending
Condition(s):Congenital Myasthenic SyndromeLast Updated:June 2, 2023No longer available
Condition(s):Myasthenic Syndromes, CongenitalLast Updated:April 2, 2021Completed
Condition(s):Myasthenic Syndromes, CongenitalLast Updated:January 5, 2024No longer available
Condition(s):Lambert-Eaton Myasthenic SyndromeLast Updated:July 9, 2019No longer available
Condition(s):Spinal Muscular Atrophy Type 3Last Updated:November 30, 2023Terminated
Condition(s):Muscular Atrophy, SpinalLast Updated:June 1, 2021Completed
Condition(s):Botulism; Iatrogenic BotulismLast Updated:March 4, 2024Recruiting
Condition(s):BotulismLast Updated:April 28, 2016Completed
Condition(s):Myasthenia Gravis, MuSKLast Updated:April 18, 2023Active, not recruiting
Condition(s):Congenital Myasthenic Syndrome; Lambert-Eaton Myasthenic Syndrome; Nystagmus, AcquiredLast Updated:September 13, 2023No longer available
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.